Comparing a specific medication to standard treatments for eye inflammation
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
This study is looking at whether adalimumab, a new type of medication, works better than traditional treatments for uveitis, an eye condition that can cause vision problems, and it's for people who are currently dealing with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10480075 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of adalimumab, a monoclonal antibody, compared to conventional immunosuppressive treatments for uveitis, a serious eye condition that can lead to blindness. Patients with uveitis often receive corticosteroids and other immunosuppressive drugs to manage their symptoms and prevent vision loss. The study aims to determine if adalimumab can provide better long-term visual outcomes without increasing side effects. Participants will be monitored for their response to treatment and any adverse effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-infectious uveitis who require immunosuppressive therapy.
Not a fit: Patients with infectious uveitis or those who do not require immunosuppressive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with uveitis, potentially preserving their vision more effectively.
How similar studies have performed: Previous studies have shown that systemic immunosuppressive therapies can be effective for uveitis, suggesting that this approach may yield positive results.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Jabs, Douglas a — Johns Hopkins University
- Study coordinator: Jabs, Douglas a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.